News | July 02, 2024
Merck and Orion announce option providing Merck global exclusive rights to Opevesostat
An investigational CYP11A1 Inhibitor, for the treatment of metastatic castration-resistant prostate cancer
An investigational CYP11A1 Inhibitor, for the treatment of metastatic castration-resistant prostate cancer
Aster CMI Hospital has successfully implemented several key digital health initiatives contributing to this accreditation
Innovative technology represents a breakthrough scientific achievement for highly contagious respiratory disease
The facility was inspected from May 7 to May 17, 2024
PEKK is a high-performance polymer family used in aerospace and other demanding markets
Ascentage Pharma has executed an Exclusive Option to License Global Rights to Olverembatinib worldwide other than China and a few other areas
New data on the secondary endpoint shows up to 52.3% of adults with fibrosis stages F1, F2 and F3 had improvement in fibrosis due to MASH
Innovative technologies and comprehensive services to strengthen Syntegon’s strategic growth
The Gavi Board today approved the Vaccine Alliance's strategy for the five-year period running from 2026 to 2030
Oligonucleotides are a unique modality with potential to address hard-to-treat diseases with high unmet need
Subscribe To Our Newsletter & Stay Updated
